Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China; Shanghai Clinical Research and Trial Center, Shanghai, China.
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Institute of Infectious Disease and Biosecurity, Shanghai Medical College of Fudan University, Shanghai, China.
Curr Opin Struct Biol. 2023 Oct;82:102667. doi: 10.1016/j.sbi.2023.102667. Epub 2023 Aug 4.
Since its outbreak in late 2019, the COVID-19 pandemic has drawn enormous attention worldwide as a consequence of being the most disastrous infectious disease in the past century. As one of the most immediately druggable targets of SARS-CoV-2, the main protease (M) has been studied thoroughly. In this review, we provide a comprehensive summary of recent advances in structural studies of M, which provide new knowledge about M in terms of its biological function, structural characteristics, substrate specificity, and autocleavage process. We examine the remarkable strides made in targeting M for drug discovery during the pandemic. We summarize insights into the current understanding of the structural features of M and the discovery of existing M-targeting drugs, illuminating pathways for the future development of anti-SARS-CoV-2 therapeutics.
自 2019 年末爆发以来,COVID-19 疫情因其是过去一个世纪最具灾难性的传染病而引起了全球的高度关注。作为 SARS-CoV-2 最具可立即成药性的靶标之一,主蛋白酶(M)已得到深入研究。在本综述中,我们全面总结了 M 的结构研究的最新进展,这些进展为 M 的生物学功能、结构特征、底物特异性和自身切割过程提供了新知识。我们考察了在疫情期间针对 M 进行药物发现的显著进展。我们总结了对 M 的结构特征和现有 M 靶向药物的发现的当前理解,为未来开发抗 SARS-CoV-2 治疗方法指明了道路。